MedChemComm
DOI: 10.1039/C5MD00364D
References
.
[
1] L.C. Cantley, The phosphoinositide 3-kinase pathway, Science, 296 (2002) 1655-1657.
2] D.A. Fruman, R.E. Meyers, L.C. Cantley, Phosphoinositide kinases, Annual review of
[
biochemistry, 67 (1998) 481-507.
3] B. Vanhaesebroeck, J. Guillermet-Guibert, M. Graupera, B. Bilanges, The emerging
mechanisms of isoform-specific PI3K signalling, Nature reviews Molecular cell biology, 11 (2010)
29-341.
4] R. Castellino, C. Muh, D. Durden, PI-3 kinase-PTEN signaling node: an intercept point for the
control of angiogenesis, Current pharmaceutical design, 15 (2009) 380-388.
5] M. Nacht, L. Qiao, M.P. Sheets, T.S. Martin, M. Labenski, H. Mazdiyasni, R. Karp, Z. Zhu, P.
[
3
[
[
Chaturvedi, D. Bhavsar, Discovery of a potent and isoform-selective targeted covalent inhibitor of
the lipid kinase PI3Kα, J. Med. Chem, 56 (2013) 712-721.
[
6] J.A. Engelman, Targeting PI3K signalling in cancer: opportunities, challenges and limitations,
Nature Reviews Cancer, 9 (2009) 550-562.
7] J.A. Engelman, P.A. Jänne, C. Mermel, J. Pearlberg, T. Mukohara, C. Fleet, K. Cichowski, B.E.
[
Johnson, L.C. Cantley, ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive
non-small cell lung cancer cell lines, Proceedings of the National Academy of Sciences of the
United States of America, 102 (2005) 3788-3793.
[8] J.M. Stommel, A.C. Kimmelman, H. Ying, R. Nabioullin, A.H. Ponugoti, R. Wiedemeyer, A.H.
Stegh, J.E. Bradner, K.L. Ligon, C. Brennan, Coactivation of receptor tyrosine kinases affects the
response of tumor cells to targeted therapies, Science, 318 (2007) 287-290.
[
9] M. Cully, H. You, A.J. Levine, T.W. Mak, Beyond PTEN mutations: the PI3K pathway as an
integrator of multiple inputs during tumorigenesis, Nature Reviews Cancer, 6 (2006) 184-192.
10] B. Markman, R. Dienstmann, J. Tabernero, Targeting the PI3K/Akt/mTOR pathway–beyond
rapalogs, Oncotarget, 1 (2010) 530.
11] J. Singh, R.C. Petter, T.A. Baillie, A. Whitty, The resurgence of covalent drugs, Nature reviews
Drug discovery, 10 (2011) 307-317.
12] S. Pezet, F. Marchand, R. D'Mello, J. Grist, A.K. Clark, M. Malcangio, A.H. Dickenson, R.J.
[
[
[
Williams, S.B. McMahon, Phosphatidylinositol 3-kinase is a key mediator of central sensitization
in painful inflammatory conditions, The Journal of Neuroscience, 28 (2008) 4261-4270.
[
13] D.A. Fruman, C. Rommel, PI3Kδ inhibitors in cancer: rationale and serendipity merge in the
clinic, Cancer discovery, 1 (2011) 562-572.
14] M. Siragusa, R. Katare, M. Meloni, F. Damilano, E. Hirsch, C. Emanueli, P. Madeddu,
[
Involvement of phosphoinositide 3-kinase γ in angiogenesis and healing of experimental
myocardial infarction in mice, Circulation research, 106 (2010) 757-768.
[
15] M. Laffargue, R. Calvez, P. Finan, A. Trifilieff, M. Barbier, F. Altruda, E. Hirsch, M.P. Wymann,
Phosphoinositide 3-kinase γ is an essential amplifier of mast cell function, Immunity, 16 (2002)
41-451.
16] A. Ghigo, F. Damilano, L. Braccini, E. Hirsch, PI3K inhibition in inflammation: Toward tailored
therapies for specific diseases, Bioessays, 32 (2010) 185-196.
17] V. Pomel, J. Klicic, D. Covini, D.D. Church, J.P. Shaw, K. Roulin, F. Burgat-Charvillon, D. Valognes,
M. Camps, C. Chabert, Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective
4
[
[